

# Pradeep Tyagi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/759113/publications.pdf>

Version: 2024-02-01

155  
papers

4,531  
citations

117453

34  
h-index

133063

59  
g-index

226  
all docs

226  
docs citations

226  
times ranked

4078  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells. <i>International Journal of Cancer</i> , 2004, 112, 693-700.	2.3	244
2	Ligand-Targeted Liposomes for Cancer Treatment. <i>Current Drug Delivery</i> , 2005, 2, 369-381.	0.8	212
3	Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. <i>International Urology and Nephrology</i> , 2010, 42, 629-635.	0.6	146
4	Controlled gene delivery system based on thermosensitive biodegradable hydrogel. <i>Pharmaceutical Research</i> , 2003, 20, 884-888.	1.7	126
5	Therapeutic receptor targets for lower urinary tract dysfunction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 437-448.	1.4	123
6	Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. <i>BJU International</i> , 2009, 104, 1476-1481.	1.3	118
7	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Liposomes. <i>Journal of Urology</i> , 2009, 182, 786-792.	0.2	118
8	Recent Advances in Intravesical Drug/Gene Delivery. <i>Molecular Pharmaceutics</i> , 2006, 3, 369-379.	2.3	102
9	Qualitative and Quantitative Expression Profile of Muscarinic Receptors in Human Urothelium and Detrusor. <i>Journal of Urology</i> , 2006, 176, 1673-1678.	0.2	95
10	Differential Expression of Functional Cannabinoid Receptors in Human Bladder Detrusor and Urothelium. <i>Journal of Urology</i> , 2009, 181, 1932-1938.	0.2	93
11	Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. <i>BJU International</i> , 2010, 106, 1681-1685.	1.3	92
12	Urinary Chemokines as Noninvasive Predictors of Ulcerative Interstitial Cystitis. <i>Journal of Urology</i> , 2012, 187, 2243-2248.	0.2	89
13	Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat. <i>Urology</i> , 2003, 61, 656-663.	0.5	86
14	Sustained Intravesical Drug Delivery Using Thermosensitive Hydrogel. <i>Pharmaceutical Research</i> , 2004, 21, 832-837.	1.7	82
15	Multiplex Analysis of Urinary Cytokine Levels in Rat Model of Cyclophosphamide-induced Cystitis. <i>Urology</i> , 2009, 73, 421-426.	0.5	75
16	Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder. <i>Journal of Physiology</i> , 2015, 593, 1857-1871.	1.3	75
17	Intraprostatic Capsaicin Injection as a Novel Model for Nonbacterial Prostatitis and Effects of Botulinum Toxin A. <i>European Urology</i> , 2007, 51, 1119-1127.	0.9	67
18	Urodynamic and Immunohistochemical Evaluation of Intravesical Capsaicin Delivery Using Thermosensitive Hydrogel and Liposomes. <i>Journal of Urology</i> , 2004, 171, 483-489.	0.2	65

#	ARTICLE	IF	CITATIONS
19	Investigations into the presence of functional $\alpha_1$ , $\alpha_2$ and $\alpha_3$ -adrenoceptors in urothelium and detrusor of human bladder. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2009, 35, 76-83.	0.7	64
20	Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. <i>World Journal of Urology</i> , 2013, 31, 241-246.	1.2	62
21	Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. <i>Urology</i> , 2003, 61, 664-670.	0.5	60
22	Functional and Immunohistochemical Characterization of CB1 and CB2 Receptors in Rat Bladder. <i>Urology</i> , 2008, 72, 1174-1178.	0.5	59
23	Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. <i>Canadian Journal of Urology</i> , 2010, 17, 4989-94.	0.0	58
24	Pathophysiology and animal modeling of underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 11-21.	0.6	54
25	Patternable Nanowire Sensors for Electrochemical Recording of Dopamine. <i>Analytical Chemistry</i> , 2009, 81, 9979-9984.	3.2	50
26	Down-Regulation of Nerve Growth Factor Expression in the Bladder by Antisense Oligonucleotides as New Treatment for Overactive Bladder. <i>Journal of Urology</i> , 2013, 190, 757-764.	0.2	47
27	Association of inflammaging (inflammation+aging) with higher prevalence of OAB in elderly population. <i>International Urology and Nephrology</i> , 2014, 46, 871-877.	0.6	45
28	Mirabegron: a safety review. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 287-294.	1.0	41
29	Hyperexcitability of Bladder Afferent Neurons Associated with Reduction of Kv1.4 $\alpha$ -Subunit in Rats with Spinal Cord Injury. <i>Journal of Urology</i> , 2013, 190, 2296-2304.	0.2	40
30	Inflammasomes are important mediators of prostatic inflammation associated with BPH. <i>Journal of Inflammation</i> , 2015, 12, 37.	1.5	40
31	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. <i>Journal of Urology</i> , 2016, 196, 599-608.	0.2	39
32	Effects of low energy shock wave therapy on inflammatory moleculars, bladder pain, and bladder function in a rat cystitis model. <i>Neurourology and Urodynamics</i> , 2017, 36, 1440-1447.	0.8	39
33	Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation. <i>Journal of Urology</i> , 2015, 194, 578-584.	0.2	38
34	Pelvic organ cross-sensitization to enhance bladder and urethral pain behaviors in rats with experimental colitis. <i>Neuroscience</i> , 2015, 284, 422-429.	1.1	37
35	Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. <i>Neurourology and Urodynamics</i> , 2011, 30, 421-427.	0.8	36
36	Upregulation of androgen-responsive genes and transforming growth factor- $\beta$ 1 cascade genes in a rat model of non-bacterial prostatic inflammation. <i>Prostate</i> , 2014, 74, 337-345.	1.2	36

#	ARTICLE	IF	CITATIONS
37	Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder. <i>Journal of Urology</i> , 2017, 197, 982-990.	0.2	36
38	Combinational effects of muscarinic receptor inhibition and $\beta_3$ -adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury. <i>Neurourology and Urodynamics</i> , 2017, 36, 1039-1045.	0.8	35
39	Bladder overactivity and afferent hyperexcitability induced by prostate $\rightarrow$ bladder cross $\rightarrow$ sensitization in rats with prostatic inflammation. <i>Journal of Physiology</i> , 2019, 597, 2063-2078.	1.3	35
40	Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms. <i>Urological Science</i> , 2010, 21, 132-136.	0.2	34
41	The effect of neutralization of nerve growth factor (NGF) on bladder and urethral dysfunction in mice with spinal cord injury. <i>Neurourology and Urodynamics</i> , 2018, 37, 1889-1896.	0.8	34
42	Drug Targets in Neurotrophin Signaling in the Central and Peripheral Nervous System. <i>Molecular Neurobiology</i> , 2018, 55, 6939-6955.	1.9	34
43	Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. <i>International Urogynecology Journal</i> , 2008, 19, 1353-1357.	0.7	33
44	Instillation of liposomes vs dimethyl sulphoxide or pentosan polysulphate for reducing bladder hyperactivity. <i>BJU International</i> , 2009, 104, 1689-1692.	1.3	33
45	Functional and Molecular Characterization of Hyposensitive Underactive Bladder Tissue and Urine in Streptozotocin-Induced Diabetic Rat. <i>PLoS ONE</i> , 2014, 9, e102644.	1.1	33
46	Bladder Uptake of Liposomes after Intravesical Administration Occurs by Endocytosis. <i>PLoS ONE</i> , 2015, 10, e0122766.	1.1	33
47	Local Drug Delivery to Bladder Using Technology Innovations. <i>Urologic Clinics of North America</i> , 2006, 33, 519-530.	0.8	32
48	Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. <i>BJU International</i> , 2012, 110, 401-407.	1.3	32
49	Addressing challenges in underactive bladder: recommendations and insights from the Congress on Underactive Bladder (CURE-UAB). <i>International Urology and Nephrology</i> , 2017, 49, 777-785.	0.6	32
50	Relaxin $\rightarrow$ 2 therapy reverses radiation $\rightarrow$ induced fibrosis and restores bladder function in mice. <i>Neurourology and Urodynamics</i> , 2018, 37, 2441-2451.	0.8	32
51	Urinary Nerve Growth Factor Levels in Urinary Tract Diseases With or Without Frequency Urgency Symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2010, 2, 88-94.	0.6	31
52	Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. <i>Gene Therapy</i> , 2009, 16, 26-33.	2.3	29
53	Neurogenic Causes of Detrusor Underactivity. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 325-331.	0.2	29
54	Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 555-570.	1.0	28

#	ARTICLE	IF	CITATIONS
55	Advances in intravesical therapy for urinary tract disorders. Expert Opinion on Drug Delivery, 2016, 13, 71-84.	2.4	27
56	Gender-based reciprocal expression of transforming growth factor- $\beta$ 1 and the inducible nitric oxide synthase in a rat model of cyclophosphamide-induced cystitis. Journal of Inflammation, 2009, 6, 23.	1.5	26
57	Neural Mechanisms Underlying Lower Urinary Tract Dysfunction. Korean Journal of Urology, 2014, 55, 81.	1.2	26
58	Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. Prostate, 2015, 75, 381-389.	1.2	26
59	Post-injury bladder management strategy influences lower urinary tract dysfunction in the mouse model of spinal cord injury. Neurourology and Urodynamics, 2017, 36, 1301-1305.	0.8	26
60	Intravesical Antisense Therapy for Cystitis Using TAT-Peptide Nucleic Acid Conjugates. Molecular Pharmaceutics, 2006, 3, 398-406.	2.3	25
61	Development of Potential Orphan Drug Therapy of Intravesical Liposomal Tacrolimus for Hemorrhagic Cystitis Due to Increased Local Drug Exposure. Journal of Urology, 2013, 189, 1553-1558.	0.2	25
62	Liposome Based Intravesical Therapy Targeting Nerve Growth Factor Ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis. Journal of Urology, 2016, 195, 1920-1926.	0.2	25
63	Distinct cellular distributions of Kv4 pore-forming and auxiliary subunits in rat dorsal root ganglion neurons. Life Sciences, 2012, 91, 258-263.	2.0	24
64	Herpes Simplex Virus Vector Mediated Gene Therapy of Tumor Necrosis Factor- $\alpha$ Blockade for Bladder Overactivity and Nociception in Rats. Journal of Urology, 2013, 189, 366-373.	0.2	24
65	Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. American Journal of Physiology - Renal Physiology, 2016, 311, F548-F554.	1.3	24
66	BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. American Journal of Physiology - Renal Physiology, 2018, 315, F45-F56.	1.3	24
67	Recent advances in imaging and understanding interstitial cystitis. F1000Research, 2018, 7, 1771.	0.8	23
68	Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU International, 2008, 101, 627-632.	1.3	22
69	Expression of E-series prostaglandin (EP) receptors and urodynamic effects of an EP <sub>4</sub> receptor antagonist on cyclophosphamide-induced overactive bladder in rats. BJU International, 2010, 106, 1782-1787.	1.3	22
70	Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). Expert Opinion on Investigational Drugs, 2016, 25, 521-529.	1.9	22
71	Functional role of cannabinoid receptors in urinary bladder. Indian Journal of Urology, 2010, 26, 26.	0.2	22
72	The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 617-627.	1.5	21

#	ARTICLE	IF	CITATIONS
73	Mirabegron, a $\beta_3$ -adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. <i>IDrugs: the Investigational Drugs Journal</i> , 2010, 13, 713-22.	0.7	21
74	Intravesical liposome therapy for interstitial cystitis. <i>International Journal of Urology</i> , 2017, 24, 262-271.	0.5	20
75	Advances in Therapeutic Development for Radiation Cystitis. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014, 6, 1-10.	0.6	18
76	Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats. <i>Human Gene Therapy</i> , 2015, 26, 734-742.	1.4	18
77	Effects of an $\alpha_1A$ -adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury. <i>Neurourology and Urodynamics</i> , 2017, 36, 1488-1495.	0.8	18
78	Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. <i>Prostate</i> , 2018, 78, 17-24.	1.2	18
79	Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4777.	1.8	18
80	Therapeutic effects of inhibition of brain-derived neurotrophic factor on voiding dysfunction in mice with spinal cord injury. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F1305-F1310.	1.3	18
81	Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin $E_2$ -induced bladder overactivity in rats. <i>BJU International</i> , 2012, 110, 1558-1564.	1.3	17
82	Advanced therapeutic directions to treat the underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 35-44.	0.6	16
83	Beta3-adrenoceptor agonists for the treatment of overactive bladder. <i>Drugs of the Future</i> , 2009, 34, 635.	0.0	16
84	Intravesical therapy for lower urinary tract symptoms. <i>Urological Science</i> , 2012, 23, 70-77.	0.2	15
85	Targeting p75 neurotrophin receptors ameliorates spinal cord injury-induced detrusor sphincter dyssynergia in mice. <i>Neurourology and Urodynamics</i> , 2018, 37, 2452-2461.	0.8	15
86	Characterization of the role of HCN channels in $\beta_3$ -adrenoceptor mediated rat bladder relaxation. <i>Bladder</i> , 2015, 2, 15.	0.6	15
87	Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015, 7, 77-83.	0.6	14
88	Nerve growth factor-dependent hyperexcitability of capsaicin-sensitive bladder afferent neurones in mice with spinal cord injury. <i>Experimental Physiology</i> , 2018, 103, 896-904.	0.9	14
89	Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 495-505.	1.3	14
90	Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy. <i>Neurourology and Urodynamics</i> , 2018, 37, 708-715.	0.8	14

#	ARTICLE	IF	CITATIONS
91	Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator. <i>Journal of Pathology</i> , 2022, 256, 442-454.	2.1	14
92	Liposomal inhibition of acrolein-induced injury in rat cultured urothelial cells. <i>International Urology and Nephrology</i> , 2014, 46, 1947-1952.	0.6	13
93	Mechanisms inducing autonomic dysreflexia during urinary bladder distention in rats with spinal cord injury. <i>Spinal Cord</i> , 2015, 53, 190-194.	0.9	13
94	Spontaneous Recovery of Reflex Voiding Following Spinal Cord Injury Mediated by Anti-inflammatory and Neuroprotective Factors. <i>Urology</i> , 2016, 88, 57-65.	0.5	13
95	Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor. <i>Life Sciences</i> , 2016, 167, 98-104.	2.0	12
96	Biomarkers for Interstitial Cystitis/Painful Bladder Syndrome. <i>Women's Health</i> , 2016, 12, 87-90.	0.7	12
97	Effect of Intravesical Liposome-Based Nerve Growth Factor Antisense Therapy on Bladder Overactivity and Nociception in a Rat Model of Cystitis Induced by Hydrogen Peroxide. <i>Human Gene Therapy</i> , 2017, 28, 598-609.	1.4	12
98	State of the art in intravesical therapy for lower urinary tract symptoms. <i>Reviews in Urology</i> , 2010, 12, e181-9.	0.9	12
99	Intravesical Liposome and Antisense Treatment for Detrusor Overactivity and Interstitial Cystitis/Painful Bladder Syndrome. <i>ISRN Pharmacology</i> , 2014, 2014, 1-12.	1.6	11
100	Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond. <i>International Urology and Nephrology</i> , 2018, 50, 401-409.	0.6	11
101	Time-dependent progression of neurogenic lower urinary tract dysfunction after spinal cord injury in the mouse model. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, F26-F32.	1.3	11
102	Low energy shock wave therapy attenuates mitochondrial dysfunction and improves bladder function in HCl induced cystitis in rats. <i>Biomedical Journal</i> , 2022, 45, 482-490.	1.4	11
103	Novel contrast mixture improves bladder wall contrast for visualizing bladder injury. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F155-F162.	1.3	10
104	Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. <i>Scientific Reports</i> , 2021, 11, 7558.	1.6	10
105	Proteomic Investigation on Chronic Bladder Irritation in the Rat. <i>Urology</i> , 2008, 71, 536-540.	0.5	9
106	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011, 3, 2-9.	0.6	9
107	Laser-capture microdissection for analysis of cell type-specific gene expression of muscarinic receptor subtypes in the rat bladder with cyclophosphamide-induced cystitis. <i>International Urology and Nephrology</i> , 2015, 47, 637-642.	0.6	9
108	Effects of liposome-based local suppression of nerve growth factor in the bladder on autonomic dysreflexia during urinary bladder distention in rats with spinal cord injury. <i>Experimental Neurology</i> , 2017, 291, 44-50.	2.0	9



#	ARTICLE	IF	CITATIONS
109	Prostate-Specific Deletion of Cdh1 Induces Murine Prostatic Inflammation and Bladder Overactivity. <i>Endocrinology</i> , 2021, 162, .	1.4	9
110	Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. <i>International Urology and Nephrology</i> , 2015, 47, 1051-1058.	0.6	8
111	Pharmacologic and Molecular Characterization of Underactive Bladder Induced by Lumbar Canal Stenosis. <i>Urology</i> , 2015, 85, 1284-1290.	0.5	8
112	MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxinâ€A injection. <i>Neurourology and Urodynamics</i> , 2018, 37, 99-105.	0.8	8
113	Longâ€lasting bladder overactivity and bladder afferent hyperexcitability in rats with chemicallyâ€induced prostatic inflammation. <i>Prostate</i> , 2019, 79, 872-879.	1.2	8
114	Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model. <i>International Urology and Nephrology</i> , 2019, 51, 617-626.	0.6	8
115	The early, longâ€term inhibition of brainâ€derived neurotrophic factor improves voiding, and storage dysfunctions in mice with spinal cord injury. <i>Neurourology and Urodynamics</i> , 2020, 39, 1345-1354.	0.8	8
116	Effect of Hyperforin-Enriched Extract on Pro-Ejaculatory Effect of 8-Hydroxy-2-(Di-N-Propylamino)Tetralin in Anesthetized Rats. <i>Urology</i> , 2007, 70, 813-816.	0.5	7
117	Early capsaicin intervention for neurogenic bladder in a rat model of spinal cord injury. <i>Biomedical Research</i> , 2007, 28, 255-259.	0.3	7
118	Therapeutic effects of nerve growth factorâ€targeting therapy on bladder overactivity in rats with prostatic inflammation. <i>Prostate</i> , 2021, 81, 1303-1309.	1.2	7
119	Constitutive expression Of NGF And P75NTR affected by bladder distension and NGF antisense treatment. <i>Life Sciences</i> , 2016, 148, 93-98.	2.0	6
120	Naked DNA for Liver Gene Transfer. <i>Advances in Genetics</i> , 2005, 54, 43-64.	0.8	5
121	URINE LEVELS OF SELECTED CHEMOKINES POSITIVELY CORRELATE WITH LOWER BLADDER CAPACITY AND PSYCHOMETRIC SCORES IN IC/PBS PATIENTS. <i>Journal of Urology</i> , 2009, 181, 21-21.	0.2	5
122	Ageâ€related changes in bladder function with altered angiotensin II receptor mechanisms in rats. <i>Neurourology and Urodynamics</i> , 2016, 35, 908-913.	0.8	5
123	Excitatory effect of acotiamide on rat and human bladder: Implications for underactive bladder treatment. <i>Life Sciences</i> , 2020, 258, 118179.	2.0	5
124	Virtual measurements of paracellular permeability and chronic inflammation via color coded pixel-wise T1 mapping. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, F506-F514.	1.3	5
125	Urodynamic effects of intravenous and intrathecal administration of Eâ€series prostaglandin 1 receptor antagonist on detrusor overactivity in rats with spinal cord injury. <i>Neurourology and Urodynamics</i> , 2018, 37, 132-137.	0.8	4
126	Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome. <i>Toxins</i> , 2019, 11, 586.	1.5	3



#	ARTICLE	IF	CITATIONS
127	Urinary Biomarkers and Benign Prostatic Hyperplasia. Current Bladder Dysfunction Reports, 2019, 14, 31-40.	0.2	3
128	Functional and histologic imaging of urinary bladder wall after exposure to psychological stress and protamine sulfate. Scientific Reports, 2021, 11, 19440.	1.6	3
129	Cystometric Changes in Pressure-guided Acute Distension Rat Model of the Underactive Bladder. Tzu Chi Medical Journal, 2009, 21, 136-139.	0.4	2
130	Role of Sarco/Endoplasmic Reticulum Calcium ATPase in Lower Urinary Tract Smooth Muscles. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S50.	0.6	2
131	Bladder Instillation of Liposomes for Bladder Coating and Drug Delivery Platform. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S90.	0.6	2
132	INTRAVESICAL LIPOSOMAL (LP08) INSTILLATION PROTECTS BLADDER UROTHELIUM FROM CHEMICAL IRRITATION. Journal of Urology, 2009, 181, 539.	0.2	2
133	1626 NON-INVASIVE IMAGING OF NEAR INFRARED DYE LABELED LIPOSOMES FACILITATES EVALUATION OF BIORESIDENCE TIME. Journal of Urology, 2010, 183, .	0.2	2
134	1954 AGE ASSOCIATED CHANGES IN URINARY PROTEOME OF OAB PATIENTS. Journal of Urology, 2011, 185, .	0.2	2
135	1153 OBESITY, INFLAMMATION AND OVERACTIVE BLADDER: PRELIMINARY RESULTS FROM A PILOT STUDY OF SERUM LEPTIN AND MCP-1 LEVELS IN MEN AND WOMEN WITH AND WITHOUT OAB SYMPTOMS. Journal of Urology, 2011, 185, .	0.2	2
136	MP4-09 EXOGENOUS OVEREXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) IN RAT BLADDER EVOKES BLADDER OVERACTIVITY. Journal of Urology, 2014, 191, .	0.2	2
137	MP89-20 BDNF OVEREXPRESSION ALTERS THE PHENOTYPE OF CHOLINERGIC NEURONS IN RAT BLADDER. Journal of Urology, 2015, 193, .	0.2	2
138	MP17-01 INFLAMMASOME ACTIVATION LEADS TO IL-18 EXPRESSION IN PROSTATIC INFLAMMATION ASSOCIATED WITH BPH. Journal of Urology, 2017, 197, .	0.2	2
139	Constitutively active HCN channels constrain detrusor excitability and modulate evoked contractions of human bladder. American Journal of Clinical and Experimental Urology, 2020, 8, 163-176.	0.4	2
140	Role of hyperpolarization-activated cyclic nucleotide-gated channels in aging bladder phenotype. Life Sciences, 2022, 289, 120203.	2.0	2
141	Targeting neurotrophin and nitric oxide signaling to treat spinal cord injury and associated neurogenic bladder overactivity. , 2022, 1, 100014.		2
142	1590 DISCRIMINATION OF OAB FROM IC/PBS BY MULTIVARIATE DATA MODELING OF URINARY PROTEINS. Journal of Urology, 2010, 183, .	0.2	1
143	1370 URINE ANALYSIS OF CONFIRMED UTI PATIENTS REVEAL HIGHER LEVELS OF CXC CHEMOKINES COMPARED TO PATIENTS WITH LUTS WITHOUT UTI. Journal of Urology, 2011, 185, .	0.2	1
144	MP76-01 INVESTIGATION INTO CONSTITUTIVE EXPRESSION OF NERVE GROWTH FACTOR IN BLADDER BY BLADDER WALL INJECTION OF NGF ANTISENSE. Journal of Urology, 2014, 191, .	0.2	1

#	ARTICLE	IF	CITATIONS
145	MP30-07 BDNF ENHANCES DETRUSOR EXCITABILITY THROUGH TRKB.T1 MEDIATED ACTIVATION OF CALCIUM CHANNELS. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
146	MP60-06 PATHOGENIC ROLE OF TRUNCATED TRKB RECEPTOR ISOFORM (TRKB.T1) IN BDNF INDUCED DETRUSOR OVERACTIVITY (DO). <i>Journal of Urology</i> , 2016, 195, .	0.2	1
147	Pathophysiology and Animal Modeling of Underactive Bladder. , 2016, , 51-68.		1
148	Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1 $\pm$ in a rat cystitis model induced by hydrogen peroxide. <i>Gene Therapy</i> , 2018, 25, 20-26.	2.3	1
149	Underactive Bladder and Bladder Outlet Procedures in Women. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 21-24.	0.2	1
150	Novel Drugs for Underactive Bladder. , 2016, , 95-114.		1
151	Urine chemokine levels correlate with treatment response to phosphodiesterase 4 inhibitor in prostatitis. <i>World Journal of Clinical Urology</i> , 2017, 6, 18.	0.0	1
152	Comparison of I-gel and LMA-Supreme Laryngeal Mask Airway in Laparoscopic Surgery: A Prospective Randomized Study. <i>Indian Journal of Public Health Research and Development</i> , 2013, 4, 298.	0.1	1
153	Localized Effects of Antimuscarinics in the Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S56.	0.6	0
154	Recent Developments in Imaging in BPS/IC. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 301-307.	0.2	0
155	246: Sensory Neuron-Specific Receptor-Mediated Regulation of Micturition Reflex in Urethane-Anesthetized Rats. <i>Journal of Urology</i> , 2007, 177, 82-82.	0.2	0